Abstract
ObjectiveThe aim of this study was to investigate whether serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1), which mediates initiation and progression of atherosclerosis in endothelial cells, could be a novel marker for peripheral artery disease (PAD) in patients with type 2 diabetes. MethodsWe evaluated relationships of serum sLOX-1 to ankle–brachial index (ABI) and examined the association of serum sLOX-1 with PAD in 410 patients with type 2 diabetes. ResultsSerum sLOX-1 was inversely correlated with ABI (r=−0.197, P<0.0001). Stepwise regression analysis demonstrated that serum sLOX-1 (β=−0.168, F=5.571, P<0.05) was independently associated with ABI, and multiple logistic regression analysis demonstrated that serum sLOX-1 (16.254 (1.237–213.651), P=0.0339) was independently associated with PAD. ConclusionsSerum sLOX-1 is associated with ABI and it could be a novel marker for PAD in patients with type 2 diabetes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
